Jadenu is a Oral Granule in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Deferasirox.
Product ID | 0078-0713_19ac4728-bb03-46b7-8221-28c2a43bc913 |
NDC | 0078-0713 |
Product Type | Human Prescription Drug |
Proprietary Name | Jadenu |
Generic Name | Deferasirox |
Dosage Form | Granule |
Route of Administration | ORAL |
Marketing Start Date | 2017-05-18 |
Marketing Category | NDA / NDA |
Application Number | NDA207968 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | DEFERASIROX |
Active Ingredient Strength | 180 mg/1 |
Pharm Classes | Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2022-12-31 |
Marketing Start Date | 2017-05-18 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA207968 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-05-18 |
Marketing Category | NDA |
Application Number | NDA207968 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2017-05-18 |
Ingredient | Strength |
---|---|
DEFERASIROX | 180 mg/1 |
SPL SET ID: | fee89140-fff1-4443-9f42-24ac004fcda1 |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI |
NDC | Brand Name | Generic Name |
---|---|---|
0078-0654 | Jadenu | deferasirox |
0078-0655 | Jadenu | deferasirox |
0078-0656 | Jadenu | deferasirox |
0078-0713 | Jadenu | Jadenu |
0078-0720 | Jadenu | Jadenu |
0078-0727 | Jadenu | Jadenu |
0078-0468 | Exjade | deferasirox |
0078-0469 | Exjade | deferasirox |
0078-0470 | Exjade | deferasirox |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
JADENU 86180574 4800484 Live/Registered |
Novartis AG 2014-01-31 |